drugset / Trial / NCT00693056
Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this Phase IIa trial is to determine the effective doses and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with erectile dysfunction (ED). The secondary objectives of this trial are to evaluate the safety and the quality of life in subjects with ED receiving RX-10100 treatment.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-03
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | clavulanic acid | Small molecule | 5 mg | — |
| Subject | clavulanic acid | Small molecule | 10 mg | — |
| Subject | clavulanic acid | Small molecule | 15 mg | — |